Mark Mcdade

Filings by Mark Mcdade span 7 companies, the busiest being PDL Biopharma, Inc., Talaris Therapeutics, Inc. and Aimmune Therapeutics, Inc. The record holds 123 filings, for trades running from 3 January 2006 to 28 October 2025.

On the open market, the record shows 5 purchases worth €3.5M and 73 sales worth €4.0M. The net balance comes to €493k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 11 share grants and 24 option exercises.

Half of the purchases are above €241k and half below.

The newest entry dates from 28 October 2025: a transaction, in Talaris Therapeutics, Inc. The last purchase on record was published on 31 January 2024, which is 1,012 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.